Ibalizumab: First Global Approval
- 166 Downloads
TaiMed Biologics is developing ibalizumab (Trogarzo™, ibalizumab-uiyk)—a humanised IgG4 monoclonal antibody—as a treatment for HIV-1 infection. Ibalizumab blocks HIV entry into CD4 cells while preserving normal immunological function and is the first CD4-directed post-attachment HIV-1 inhibitor and the first humanised monoclonal antibody for the treatment of HIV/AIDS. This article summarizes the milestones in the development of ibalizumab leading to this first approval in HIV-1 treatment.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. A. Markham, a contracted employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 1.US FDA. FDA approves new HIV treatment for patients who have limited treatment options [media release]. 6 Mar 2018. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm599657.htm.
- 2.US FDA. TROGARZO™ (ibalizumab-uiyk): US prescribing Information. 2018. www.accessdata.fda.gov/drugsatfda_docs/label/2018/761065lbl.pdf. Accessed 21 Mar 2018.
- 3.Genentech Inc. Genentech announces expiration of Hart-Scott-Rodino waiting period and completes acquisition of Tanox [media release]. 3 Aug 2007. http://www.gene.com.
- 4.TaiMed Biologics. WuXi PharmaTech to manufacture ibalizumab for TaiMed Biologics [media release]. 28 Aug 2012. http://www.taimedbiologics.com.
- 5.Theratechnologies, TaiMed Biologics. Theratechnologies and TaiMed Biologics sign exclusive marketing and distribution agreement for ibalizumab [media release]. 18 Mar 2016. http://www.theratech.com.
- 6.US FDA. Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=321910. Accessed 10 Apr 2018.
- 9.Weinheimer S, Cohen Z, Marsolais C, et al. Ibalizumab susceptibility in patient HIV isolates resistant to antiretrovirals [abstract no. 561]. In: 25th Conference on Retroviruses and Opportunistic Infections. 2018.Google Scholar
- 11.Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009;53(2):450–7.CrossRefPubMedGoogle Scholar
- 12.Lalezari J, Fessel WJ, Schrader S, et al. Primary efficacy endpoint and safety results of ibalizumab in a phase 3 study of heavily treatment-experienced patients with multidrug-resistant human immunodeficiency virus-1 infection [abstract no. LB-6 plus oral presentation]. Open Forum. Infectious Diseases. 2016;3(Suppl. 1):S1.Google Scholar
- 13.Lewis S, Fessel J, Emu B, et al. Long-acting ibalizumab in patients with multi-drug resistant HIV-1: a 24-week study [abstract no. 438 plus poster 449LB]. In: 24th conference on retroviruses and opportunistic infections. 2017.Google Scholar
- 14.Emu B, Fessel WJ, Schrader S, et al. Forty-eight-week safety and efficacy on-treatment analysis of ibalizumab in patients with multi-drug resistant HIV-1 [abstract no. 1686 plus oral presentation]. Open Forum. Infect Dis. 2017;4(Suppl. 1):S38–9.Google Scholar
- 15.Khanlou H, Gathe JJ, Schrader S, et al. Safety, efficacy, and pharmacokinetics of ibalizumab in treatment-experienced HIV-1 infected patients: a phase 2b study [abstract no. H2-794b plus oral presentation]. In: 51st Interscience Conference on Antimicrobial Agents and Chemotherapy. 2011.Google Scholar